
Glenmark Pharmaceuticals is a leading Indian pharmaceutical company that was founded in 1970 by GlaxoSmithKline and Dr. Gracias. The company is headquartered in Mumbai, India.
Glenmark Pharmaceuticals has a diverse portfolio of products that include APIs, formulations, and biologics. The company has a strong presence in the global market, with operations in over 50 countries.
Glenmark Pharmaceuticals has a market capitalization of over $2 billion and is listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). The company has a large and diverse shareholder base.
The company's shareholding pattern is dominated by institutional investors, with the largest shareholder being the company's promoter group, Glenmark Group.
Suggestion: Microstrategy Shareholder Meeting Vote Proposals
Quality and Compliance
Glenmark Pharmaceuticals has faced quality control issues at multiple plants.
The US FDA sent Glenmark a warning letter in October 2019 after an inspection of the company's plant in Himachal Pradesh, detailing "significant violations of current good manufacturing practice."
Glenmark's plant near Charlotte, North Carolina was recalled in August 2021 due to quality concerns, and a subsequent FDA investigation in 2022 documented 17 manufacturing standard violations.
Additional reading: Fmla Violations Fines
The FDA sent another warning letter to Glenmark in November 2022 regarding its plant in Goa, India, citing a lack of procedures to verify the strength, quality, and purity of produced drugs.
Glenmark's product Telma-H was subject to a 'Not of Standard Quality' alert by India's CDSCO in September 2024, although the company claimed they had not produced the drug.
The FDA has sent Glenmark multiple warning letters, including one in July 2025 after an inspection of the company's plant in Madhya Pradesh uncovered problems with cleaning and drug testing.
Glenmark's management oversight and control over drug manufacturing has been deemed inadequate by the FDA, citing repeated failures at multiple sites.
A unique perspective: Multiple Factor Models
Financial Performance
Glenmark Pharmaceuticals has consistently shown growth in sales over the years, with a compounded annual growth rate of 7% over the past 10 years.
The company's sales have been steadily increasing, with a total of ₹13,342 crore in sales for the 4-year period ending in 2023.
Here's a breakdown of the company's sales over the years:
The company's operating profit margin (OPM) has also been steadily increasing, with an OPM of 18% in 2023, up from 10% in 2022.
Profit & Loss

The profit and loss statement is a crucial part of any company's financial performance. It shows the revenue earned and the expenses incurred over a specific period.
Sales have been steadily increasing over the years, with a 5-year compounded growth rate of 5% and a 10-year compounded growth rate of 7%.
The operating profit margin (OPM) has fluctuated between 10% and 22% over the past decade, with an average of 18%. In 2023, the OPM was 18%.
Other income has been a mixed bag, ranging from a loss of Rs. 180 in 2015 to a gain of Rs. 375 in 2018. In 2024, other income was a loss of Rs. 449.
Here's a breakdown of the company's expenses over the years:
Depreciation has been increasing steadily, with a 10-year compounded growth rate of 17%. In 2024, depreciation was Rs. 486.
The profit before tax has been volatile, ranging from a low of Rs. 544 in 2015 to a high of Rs. 1,491 in 2017. In 2024, profit before tax was Rs. 868.
The tax rate has fluctuated between 22% and 61%, with an average of 29%. In 2024, the tax rate was 25%.
Net profit has been affected by the fluctuations in profit before tax and tax rate. In 2024, net profit was a loss of Rs. 1,434.
Pharma Shares in Focus on $1.1 Billion Deal
Glenmark Pharma shares are in focus due to a significant deal worth $1.1 billion.
The company's unit Glenmark Specialty S.A. has signed an exclusive licensing agreement with China's Hengrui Pharma.
This deal is for Trastuzumab Rezetecan, a next-gen HER2-targeting ADC.
The upfront payment for this deal is $18 million.
Milestone payouts of up to $1.093 billion are also part of the agreement.
The deal includes royalties on sales, adding to the total value.
Record Date for Interim Dividend
The record date for the payment of an interim dividend is a crucial deadline for shareholders. It will be Tuesday, September 30, 2025, as announced by Glenmark Pharmaceuticals.
Glenmark Pharmaceuticals has informed its shareholders about the record date for the interim dividend.
A unique perspective: Record Deal vs Distribution Deal
Shareholding and Governance
Glenmark Pharmaceuticals has a stable shareholding pattern, with promoters holding a consistent 46.65% stake since Dec 2022.
Promoters have maintained their stake, while the number of shareholders has fluctuated, with a high of 300,106 in Dec 2022 and a low of 198,789 in Sep 2025.
The company has seen a shift in ownership among other categories, with Foreign Institutional Investors (FIIs) decreasing from 34.78% in Mar 2017 to 20.73% in Sep 2025, and Domestic Institutional Investors (DIIs) increasing from 6.02% in Mar 2017 to 18.61% in Sep 2025.
Shareholding Pattern
The shareholding pattern of a company is a crucial aspect of its governance. The data from the article reveals that the promoters have maintained a consistent shareholding of around 46.65% over the past few years.
One notable trend is the decrease in the number of shareholders, from 300,106 in Dec 2022 to 190,210 in Jun 2025. This indicates a potential consolidation of shares among larger investors.
The data also shows a significant increase in the shareholding of DIIs (Domestic Institutional Investors), from 10.69% in Dec 2022 to 18.61% in Sep 2025. This suggests a growing interest in the company among domestic institutional investors.
Here's a breakdown of the shareholding pattern over the past few years:
The addition of new classifications and details in the XBRL format from Sep 2022 onwards has provided more insight into the company's shareholding pattern. This includes the inclusion of banks and foreign portfolio investors, which may be contributing to the changes in FII and DII shareholdings.
Shareholder Ballot Report
Shareholder Ballot Report is a crucial document that outlines the voting results of a company's shareholder meeting or postal ballot.
Glenmark Pharmaceuticals releases a Scrutinizer's Report that includes the voting results under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
A unique perspective: Shareholder Rights Plan
This report is enclosed with the shareholder meeting notice, providing transparency into the voting process.
The Scrutinizer's Report is a formal document that ensures the accuracy and authenticity of the voting results.
Glenmark Pharmaceuticals also releases the Proceedings of the Annual General Meeting (AGM), which includes the outcome of the AGM.
The 47th AGM of the Company is an important milestone that marks the company's progress and achievements.
The postal ballot outcome of the AGM is a key aspect of the Proceedings document, highlighting the shareholders' decisions.
A different take: Bill of Exchange Document
Funding and Investors
Glenmark Pharmaceuticals has raised funding over 1 round.
The company has 3 institutional investors, including Actis, British International Investment, and Plexus Ventures.
Legal Entities
Glenmark Pharmaceuticals has several legal entities associated with it, including Glenmark Pharmaceuticals Distribution s.r.o. in the Czech Republic, which was incorporated on January 18, 2016, and is currently active.
GlenmarkCIN, a subsidiary in Latvia, was deadpooled after being incorporated on August 2, 2017. It had a revenue of $5.19K as of December 31, 2018, and employed 2 people at that time.
The oldest legal entity is Glenmark Pharmaceuticals Limited, which was incorporated in India on November 18, 1977. It has a revenue of $1.53B as of March 31, 2024, and employs 13593 people as of April 30, 2025.
Here is a list of Glenmark Pharmaceuticals' legal entities:
Business Operations
Glenmark Pharmaceuticals has a strong presence in the global market, with a focus on research and development. The company has a significant presence in over 50 countries.
Glenmark Pharmaceuticals has a diverse portfolio of products, including APIs, formulations, and biosimilars. Its commitment to innovation has led to the development of several first-to-file products in the US market.
The company's business operations are driven by its core values of quality, innovation, and customer satisfaction. This focus has enabled Glenmark Pharmaceuticals to establish long-term relationships with its customers and partners.
Intriguing read: Focus Group Holdings Limited
Marketed Drugs
Glenmark Pharmaceuticals Ltd has a commercialized product portfolio that includes marketed drugs. This portfolio is a key aspect of their business operations.
Their marketed drugs cater to various therapeutic areas, including respiratory, dermatology, and oncology. This diversification helps the company stay competitive in the market.
One of their notable marketed drugs is a respiratory medication, which is used to treat chronic obstructive pulmonary disease (COPD). This medication is a crucial part of their portfolio, contributing to their revenue.
Another area where they have a strong presence is in dermatology, with a marketed drug used to treat skin conditions such as acne and psoriasis.
Clinical Trials
To stay ahead in the market, it's essential to understand Glenmark Pharmaceuticals Ltd's clinical trial strategy. This involves determining their go-to-market proposition and gaining insight into their clinical operations, recruitment, and trial strategy.
Glenmark Pharmaceuticals Ltd's clinical trials are crucial for commercializing their products. By identifying which products will be commercialized, you can better contend with shifting product portfolios.
Clinical trials are a key part of Glenmark Pharmaceuticals Ltd's business operations. This helps the company stay competitive and adapt to market changes.
You might enjoy: Virtual Debit Card for Free Trial

Understanding Glenmark Pharmaceuticals Ltd's clinical trial strategy can help you make informed decisions about their products. This includes identifying which products will be commercialized and how they will be marketed.
By staying informed about Glenmark Pharmaceuticals Ltd's clinical operations, recruitment, and trial strategy, you can make more accurate predictions about their future product offerings.
If this caught your attention, see: Docusign Free Trial Limitations
Competitor Comparison
As we take a closer look at the business operations of pharmaceutical companies, it's interesting to see the different headquarters of these companies. Glenmark Pharmaceuticals Ltd is based in India, while Teva Pharmaceutical Industries Ltd has its headquarters in Israel.
The size of the companies can also give us a glimpse into their operations. Interestingly, Dr. Reddy's Laboratories Ltd has the smallest number of employees with 26,944, while Teva Pharmaceutical Industries Ltd has the largest with 37,000 employees.
Here's a breakdown of the number of employees for each company:
Looking at the state or province where each company is based can also give us some insight into their operations. Glenmark Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd are both based in the state of Maharashtra in India.
News and Announcements

Glenmark Pharmaceuticals recently had a Shareholder Meeting / Postal Ballot-Scrutinizer's Report, where they approved their FY24-25 financials and appointed Patricia Andrews as an independent director.
The meeting also approved a Rs2.50/share dividend, which is a significant development for shareholders.
The company's Board Meeting Outcome revealed an Interim dividend of ₹2.50/share, amounting to ₹705.50m, with a record date of Oct 3, 2025.
Worth a look: Retained Cash Flow / Net Debt
Announcements
The company has announced a shareholder meeting and postal ballot outcome, with the AGM held on September 26, 2025, approving the FY2024-25 audited financials and a Rs.2.50 dividend.
The AGM also saw the appointment of Patricia Andrews as an independent director. The company has approved a dividend of Rs.2.50/share, with a record date of October 3, 2025.
Here are the key dates related to the dividend:
- Record date: October 3, 2025
- Interim dividend: ₹2.50/share (₹705.50m)
The company has also announced an exclusive license for Trastuzumab Rezetecan, a deal worth $18M upfront, with up to $1.093B in milestones.
Press Release under Regulation 30 (LODR)
Glenmark Pharmaceuticals has made an announcement under Regulation 30 (LODR) through a press release.
This type of announcement is a requirement for companies listed on the stock exchange, and it's a way for them to share important information with the public and the regulatory bodies.
Glenmark Pharmaceuticals made this announcement to share news about strengthening its oncology portfolio with Hengrui's HER2 targeting ADC for multiple regions.
Take a look at this: Meta Ai Announcement
Stocks in News: Adani Energy, Dr. Reddy's, Tata Motors, Newgen Software
Adani Energy Solutions achieved a significant milestone by obtaining 'Zero-Waste-to-Landfill' certification, a testament to their commitment to sustainability.
Dr Reddy's and Hetero Labs have partnered to sell generic HIV prevention drugs, making essential medications more accessible to those in need.
Tata Motors is currently facing supplier payment issues due to a cyberattack, highlighting the importance of robust cybersecurity measures in the corporate world.
Newgen Software has not been mentioned in the article section, so let's move on to another topic.
Investor Information
Glenmark Pharmaceuticals has raised funding over 1 round.
The company has secured funding from a variety of sources, but we don't know much about the details of these investments.
Glenmark Pharmaceuticals has 3 institutional investors including Actis, British International Investment and Plexus Ventures.
These investors have likely played a significant role in the company's growth and development over the years.
Glenmark Pharmaceuticals has had the support of Actis, a well-established investor in the pharmaceutical industry.
British International Investment and Plexus Ventures have also been instrumental in the company's success.
We don't have information on the specific amounts or terms of the funding rounds, but it's clear that Glenmark Pharmaceuticals has had the backing of some major players in the industry.
Here's an interesting read: Does Klarna Report to Credit Bureaus If You Don't Pay
Frequently Asked Questions
Where are Glenmark drugs manufactured?
Glenmark drugs are manufactured in locations including Monroe, North Carolina, USA, and India at facilities in Goa, Baddi, Nalagarh, and Sikkim. Learn more about Glenmark's global manufacturing presence.
Featured Images: pexels.com


